Literature DB >> 12379620

Treatments no longer in development for rheumatoid arthritis.

E Keystone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379620      PMCID： PMC1766723          DOI： 10.1136/ard.61.suppl_2.ii43

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

Review 1.  Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis.

Authors:  J A van Roon; F P Lafeber; J W Bijlsma
Journal:  Arthritis Rheum       Date:  2001-01

2.  Synovial tissue response to treatment with Campath-1H.

Authors:  E M Ruderman; M E Weinblatt; L M Thurmond; G S Pinkus; E M Gravallese
Journal:  Arthritis Rheum       Date:  1995-02

3.  Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.

Authors:  E J Lewis; J Bishop; K M Bottomley; D Bradshaw; M Brewster; M J Broadhurst; P A Brown; J M Budd; L Elliott; A K Greenham; W H Johnson; J S Nixon; F Rose; B Sutton; K Wilson
Journal:  Br J Pharmacol       Date:  1997-06       Impact factor: 8.739

4.  In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis.

Authors:  N J Olsen; G P Teal; V Strand
Journal:  Clin Immunol Immunopathol       Date:  1993-05

5.  Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity.

Authors:  K Connolly; J R Roubinian; D Wofsy
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

6.  Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment. Implications for therapeutic approaches on autoimmune arthritis.

Authors:  T J Goldschmidt; M Andersson; V Malmström; R Holmdahl
Journal:  Immunobiology       Date:  1992-04       Impact factor: 3.144

7.  Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection.

Authors:  E L Matteson; D E Yocum; E W St Clair; A A Achkar; M S Thakor; M R Jacobs; A E Hays; C K Heitman; J M Johnston
Journal:  Arthritis Rheum       Date:  1995-09

8.  Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.

Authors:  P P Tak; P A van der Lubbe; A Cauli; M R Daha; T J Smeets; P M Kluin; A E Meinders; G Yanni; G S Panayi; F C Breedveld
Journal:  Arthritis Rheum       Date:  1995-10

9.  Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.

Authors:  N L Carteron; C L Schimenti; D Wofsy
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

10.  A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.

Authors:  P A van der Lubbe; B A Dijkmans; H M Markusse; U Nässander; F C Breedveld
Journal:  Arthritis Rheum       Date:  1995-08
View more
  8 in total

1.  Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis.

Authors:  Bon-A Cho; Ji Hyun Sim; Ji Ah Park; Hye Won Kim; Wan-Hee Yoo; Seung-Hyun Lee; Dong-Sup Lee; Jae Seung Kang; Young-Il Hwang; Wang Jae Lee; Insoo Kang; Eun Bong Lee; Hang-Rae Kim
Journal:  J Clin Immunol       Date:  2012-02-25       Impact factor: 8.317

2.  Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway.

Authors:  Yun-Gyoung Hur; Chang-Hee Suh; Sungjoo Kim; Jonghwa Won
Journal:  J Clin Immunol       Date:  2006-12-29       Impact factor: 8.317

Review 3.  Of mice and men: how animal models advance our understanding of T-cell function in RA.

Authors:  Tamás Kobezda; Sheida Ghassemi-Nejad; Katalin Mikecz; Tibor T Glant; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-01-07       Impact factor: 20.543

Review 4.  The pathogenesis of rheumatoid arthritis: new insights from old clinical data?

Authors:  Josef S Smolen; Daniel Aletaha; Kurt Redlich
Journal:  Nat Rev Rheumatol       Date:  2012-03-13       Impact factor: 20.543

5.  The Development of Novel Therapies for Rheumatoid Arthritis.

Authors:  Ling-Dong Quan; Geoffrey M Thiele; Jun Tian; Dong Wang
Journal:  Expert Opin Ther Pat       Date:  2008-07       Impact factor: 6.674

Review 6.  Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.

Authors:  Yasuto Araki; Toshihide Mimura
Journal:  Int J Mol Sci       Date:  2017-04-25       Impact factor: 5.923

Review 7.  MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.

Authors:  Lukas Muri; David Leppert; Denis Grandgirard; Stephen L Leib
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

8.  Self-reactive T cells induce and perpetuate chronic relapsing arthritis.

Authors:  Jonatan Tuncel; Jens Holmberg; Sabrina Haag; Malin Hultqvist Hopkins; Lena Wester-Rosenlöf; Stefan Carlsen; Peter Olofsson; Rikard Holmdahl
Journal:  Arthritis Res Ther       Date:  2020-04-28       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.